Found 16 articles for: "Acne Vulgaris"
Effective With Minimal Side Effects: A Novel Treatment Regimen for Acne Vulgaris Using Multifunctional Ingredients
December 2024 | Volume 23 | Issue 12 | Original Article | 1042 | Copyright © December 2024
Background: There are numerous over-the-counter products for treating acne, although many formulations have tolerability issues and lack the cosmetic elegance desired by adult pa...
Read MoreTreatment of Mild to Severe Acne Vulgaris With a 650-Microsecond 1064-nm Nd:YAG Laser
November 2024 | Volume 23 | Issue 11 | Original Article | 957 | Copyright © November 2024
Background: Effective treatment of acne remains a challenge to dermatologists.Objective: To evaluate the efficacy and tolerability of a 650-microsec...
Read MoreTreatment of Acne Vulgaris-Associated Post-Inflammatory Dyschromia With Combination of Non-Ablative Laser Therapy and Topical Antioxidants
September 2024 | Volume 23 | Issue 9 | Original Article | 769 | Copyright © September 2024
Acne can cause disfiguring sequelae, such as scarring, post-inflammatory erythema (PIE), and post-inflammatory hyperpigmentation (PIH). These post-inflammatory dyschromias pose a significant psyc...
Read MoreUnited Arab Emirates Consensus Recommendations for Management of Acne Vulgaris
August 2024 | Volume 23 | Issue 8 | Original Article | 653 | Copyright © August 2024
Acne in the United Arab Emirates is a common disease that causes burden to patients, has psychosocial impacts, and is associated with physical sequelae such as dyspigmentation and scarring. This ...
Read MoreIntegrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne Vulgaris
January 2024 | Volume 23 | Issue 1 | Original Article | 1278 | Copyright © January 2024
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged 12 years or older based on results from two identical pivotal Phase 3 trials. In...
Read MoreSeasonal Patterns in Tetracycline-Associated Hyperpigmentation Among Patients With Acne Vulgaris
November 2023 | Volume 22 | Issue 11 | Features | e9 | Copyright © November 2023
Background: Oral tetracyclines (TCNs) are commonly prescribed for acne, but they have been shown to increase the risk of hyperpigmentation, particularly in the setting of sun exp...
Read MoreLong-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris
August 2023 | Volume 22 | Issue 8 | Original Article | 810 | Copyright © August 2023
Background: Clascoterone cream 1% is approved for the treatment of acne vulgaris in patients aged ≥ 12 years based on results from two 12-week Phase 3 studies in patients with...
Read MoreCeramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment
June 2023 | Volume 22 | Issue 6 | Original Article | 554 | Copyright © June 2023
Barrier damage caused by facial acne vulgaris can be magnified by topical medication, such as adapalene (0.3%) and benzoyl peroxide (2.5%)(A/BPO), which utilizes a retinoid to normalize follicula...
Read MoreEfficacy and Safety of 1% Clascoterone Cream in Patients Aged > 12 Years With Acne Vulgaris
February 2023 | Volume 22 | Issue 2 | Original Article | 174 | Copyright © February 2023
Background: Two randomized phase 3 studies evaluated efficacy and safety of 1% clascoterone cream, a topical androgen receptor inhibitor, in patients aged ≥9 years with modera...
Read MorePatient Preferences for Acne Vulgaris Treatment and Barriers to Care: A Survey Study
November 2022 | Volume 21 | Issue 11 | Original Article | 1191 | Copyright © November 2022
The associated direct and indirect costs of acquiring acne vulgaris (acne) treatment from a clinician may prohibit some patients from doing so. Barriers to care may also influence patient preferences ...
Read MoreReview of Tretinoin-Benzoyl Peroxide in The Treatment of Acne Vulgaris
October 2022 | Volume 21 | Issue 10 | Original Article | 1098 | Copyright © October 2022
Background: Acne vulgaris has a multifactorial pathogenesis, and combination therapy is recommended in most patients. A tretinoin 0.1%/benzoyl peroxide 3% (Tret-BPO) cream which uses ...
Read MoreEfficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris
July 2022 | Volume 21 | Issue 7 | | 713 | Copyright © July 2022
Background: Although truncal acne is thought to have the same pathophysiology as facial acne, treatment response may differ based on body area involvement. Traditionally, prescribers ...
Read MoreHormonal Therapies in the Management of Acne Vulgaris
June 2022 | Volume 21 | Issue 6 | | 618 | Copyright © June 2022
Acne vulgaris is a multifactorial chronic disorder of the pilosebaceous unit. Established treatments include topical retinoids, antibiotics in mild cases, and oral antibiotics and isotretinoin in mode...
Read MoreApplications of Gold and Silver Nanoparticles in the Treatment of Acne Vulgaris: A Systematic Review
June 2021 | Volume 20 | Issue 6 | | 666 | Copyright © June 2021
Background: Current treatments for acne are often accompanied by undesirable side effects and contribute to antibiotic resistance. Gold and silver nanoparticles are an emerging treatm...
Read MoreAcne Vulgaris: The Majority of Patients Do Not Achieve Success According to FDA Guidance
June 2021 | Volume 20 | Issue 6 | | 648 | Copyright © June 2021
Background: The Food and Drug Administration (FDA) recommends grading Acne vulgaris via an Investigator’s Global Assessment (IGA) scale and assessing treatment as either success...
Read MoreTolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris
March 2021 | Volume 20 | Issue 3 | | 295 | Copyright © March 2021
Acne vulgaris is the most common dermatological disorder worldwide, causing significant physical and psychological morbidity. Topical combination therapy has shown superior efficacy compared to monoth...
Read More© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
